Please login to the form below

Not currently logged in
Email:
Password:

Teva's Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role

Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer.

He joins the Irish biopharma company from Teva, where he served as general manager of its US respiratory division, and prior to that he held senior roles at GlaxSmithKline and Altana.

Amarin’s president and CEO John Thero said: "Mark brings a strong track record of success coupled with valuable experience and proven leadership to our management team to help drive our anticipated expansion.

"We expect Mark's driven, people-oriented, hands-on approach to work well with our existing commercial organisation to help build on our growth.”

Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of results from the REDUCE-IT cardiovascular outcomes trial. The 8,000-patient study involves its first FDA-approved product, the omega-3 fatty acid-based Vascepa.

21st September 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....